Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company focused on neuroscience and oncology. After a strong run that lifted shares well above $260 earlier in 2026, the stock has pulled back to roughly $208, raising the question of whether it can climb back toward the levels most analysts still model for it.
Jazz Pharmaceuticals enjoys a predominantly bullish sell-side view, with most covering analysts rating the shares Buy or Overweight. The targets reviewed here span from about $225 on the cautious end to $337 at the top, with the calculated mean landing near $294, rounded to a central target of $295.
The highest targets come from Goldman Sachs (initiated at $337 in September 2026) and UBS (which raised its target to $337), while Morgan Stanley sits at $322 and Bank of America at $313. A cluster of firms, including Piper Sandler, Needham, Wells Fargo, Deutsche Bank, and Canaccord Genuity, hold targets around $300 to $310. Barclays ($271), J.P. Morgan ($276), and Stifel ($275) sit toward the middle, while RBC ($258) and Bernstein ($229) represent the more cautious views. Bernstein notably initiated coverage with a Market Perform rating, arguing that much of the oncology upside is already reflected in the valuation.
Bullish analysts emphasize the durability of the neuroscience franchise and the potential of Ziihera and zanidatamab; more cautious analysts point to execution risk and competition in oncology. The wide target range is a reminder that the mean is a midpoint of opinions, not a guarantee.
Jazz shares recently traded around $208, with a 52-week range of roughly $129 to $266 and a market capitalization near $13.6 billion. Reaching the $295 central target from $208 would require a gain of about 42%, a substantial move by any standard and one that would take the stock well above its prior 52-week high.
The path is fundamentally driven. The company reported mixed results in its most recent quarter: revenue of about $1.21 billion exceeded expectations and rose 15.5% year over year, while adjusted EPS (earnings per share) of $5.71 came in below consensus. Full-year 2026 revenue guidance of roughly $4.25 billion to $4.5 billion frames the near-term growth outlook. On valuation, the stock trades at a modest price-to-earnings ratio, and some analysts cite an enterprise value to 2027 EBITDA (earnings before interest, taxes, depreciation, and amortization) multiple of about eight times as leaving room for re-rating if pipeline execution succeeds.
The central bull case rests on Ziihera, a HER2-targeted therapy that received FDA clearance and benefits from Breakthrough Therapy designations for first-line HER2-positive gastric and gastroesophageal cancer, supported by the Phase 3 HERIZON-GEA-01 trial. Additional indications, including potential breast cancer settings, represent optionality that analysts model into higher targets.
The neuroscience portfolio, anchored by products such as Xywav and Epidiolex, generates substantial cash flow that funds oncology investment. Analysts also note that oxybate-related competitive pressure has so far been less severe than feared, and the company completed a share repurchase program covering roughly 4% of shares outstanding, signaling management confidence.
Jazz's legacy neurology blockbusters still represent a large share of product revenue and face patent expirations and generic competition that could erode earnings visibility. In oncology, competition from therapies such as Enhertu could cap market share for Jazz's HER2 franchise, and execution risk across multiple launches remains a concern.
Guidance that tracks only slightly above or below prior Street forecasts could limit multiple expansion, and a recent leadership change in the commercial organization adds transition risk. If pipeline data disappoint or oncology launches scale more slowly than modeled, the valuation could compress toward the lower end of the analyst range.
From a technical perspective, Jazz is trading below its 50-day moving average near $241 and its 200-day moving average near $232, indicating the stock is in a corrective phase after a strong multi-month advance. The 52-week high near $266 is the key overhead resistance level; a decisive move above it would be required before the $295 target becomes technically relevant. On the downside, the $200 round-number level and the prior low near $129 frame the broader range. The stock's low beta reflects its defensive, cash-generating profile.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch quarterly earnings and full-year guidance updates, Ziihera and zanidatamab launch progress and additional clinical readouts, oxybate generic competition trends, and any changes in analyst ratings or targets. Regulatory decisions and presentations at major oncology meetings are also key catalysts for the pipeline narrative.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. For investors tracking JAZZ alongside hundreds of other names, the tool offers a way to surface actionable changes in momentum without constant manual review.
The $295 central target for Jazz Pharmaceuticals is an analyst-derived figure, reflecting the average of roughly 20 current price targets that range from about $225 to $337. It implies a substantial gain of roughly 42% from the recent price near $208. The bull case rests on Ziihera's oncology expansion and resilient neuroscience cash flows, while the bear case centers on patent erosion, competition, and execution risk. The wide analyst range shows meaningful disagreement about how much pipeline upside is already priced in. Reaching the target would require clearing the prior 52-week high near $266 and sustained pipeline execution; failure to deliver on oncology launches could keep the stock range-bound. Investors should monitor earnings, guidance, launch progress, and clinical data rather than treat the target as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To JAZZ | 1D Price Change % | ||
|---|---|---|---|---|
| JAZZ | 100% | -0.84% | ||
| ZYME - JAZZ | 51% Loosely correlated | +4.48% | ||
| AMLX - JAZZ | 43% Loosely correlated | +0.90% | ||
| CLDX - JAZZ | 40% Loosely correlated | -3.04% | ||
| JBIO - JAZZ | 39% Loosely correlated | +1.82% | ||
| DYN - JAZZ | 37% Loosely correlated | -1.23% | ||
More | ||||